Vitamin D and its analogs have antiproteinuric activity and podocytes express the vitamin D receptor, but whether vitamin D signaling in podocytes accounts for this renoprotection is unknown. To investigate this question, we used the 2.5 kb podocin promoter to target Flag-tagged human vitamin D receptor (hVDR) to podocytes in DBA/2J mice. After the induction of diabetes with streptozotocin, transgenic mice had less albuminuria than wild-type controls. In transgenic mice, a low dose of the vitamin D analog doxercalciferol prevented albuminuria, markedly attenuated podocyte loss and apoptosis, and reduced glomerular fibrosis, but it had little effect on the progression of diabetic nephropathy in wild-type mice. Moreover, reconstitution of VDR-null mice with the hVDR transgene in podocytes rescued VDR-null mice from severe diabetes-related renal damage. In culture, 1,25-dihydroxyvitamin D suppressed high-glucose-induced apoptosis of podocytes by blocking p38-and ERK-mediated proapoptotic pathways. Taken together, these data provide strong evidence that vitamin D/VDR signaling in podocytes plays a critical role in the protection of the kidney from diabetic injury. 23: 197723: -198623: , 201223: . doi: 10.1681 Podocytes play a key role in the regulation of glomerular filtration in the kidney. The foot processes of podocytes are an integral part of the glomerular filtration barrier that keeps proteins and other large molecules from being filtered into the urine. Podocytes synthesize proteins that are key components of the slit diaphragm formed between adjacent interdigitating foot processes that functions as the major size-and charge-selective barrier to protein leakage. 1 Therefore, podocyte injury, loss, or death leads to albuminuria, a major risk factor for the progression of CKD, renal failure, cardiovascular events, and death. 2 A body of literature has documented the antiproteinuric activity of vitamin D and its analogs. 3 Vitamin D insufficiency is associated with increased prevalence of albuminuria in the general population. 4 High prevalence of vitamin D deficiency is common in patients with CKD, 5 mainly as a result of renal dysfunction and abnormal vitamin D metabolism. 6 A number of recent randomized clinical trials have confirmed the antiproteinuric activity of vitamin D analogs in diabetic patients with CKD. 7, 8 Potent antiproteinuric activity of vitamin D has also be demonstrated in a variety of animal models of kidney disease. 3 Treatment with 1,25-dihydroxyvitamin D (1,25(OH) 2 D 3 ) or activated vitamin D analogs reduced albuminuria and prevented podocyte injury in 5/6 nephrectomized rats, 9-11 puromycin aminonucleoside-induced podocyte apoptosis, 12 and adriamycin-induced nephropathy. 13 We reported that vitamin D analog therapy reduced albuminuria and prevented podocyte loss in experimental
Podocytes play a key role in the regulation of glomerular filtration in the kidney. The foot processes of podocytes are an integral part of the glomerular filtration barrier that keeps proteins and other large molecules from being filtered into the urine. Podocytes synthesize proteins that are key components of the slit diaphragm formed between adjacent interdigitating foot processes that functions as the major size-and charge-selective barrier to protein leakage. 1 Therefore, podocyte injury, loss, or death leads to albuminuria, a major risk factor for the progression of CKD, renal failure, cardiovascular events, and death. 2 A body of literature has documented the antiproteinuric activity of vitamin D and its analogs. 3 Vitamin D insufficiency is associated with increased prevalence of albuminuria in the general population. 4 High prevalence of vitamin D deficiency is common in patients with CKD, 5 mainly as a result of renal dysfunction and abnormal vitamin D metabolism. 6 A number of recent randomized clinical trials have confirmed the antiproteinuric activity of vitamin D analogs in diabetic patients with CKD. 7, 8 Potent antiproteinuric activity of vitamin D has also be demonstrated in a variety of animal models of kidney disease. 3 Treatment with 1,25-dihydroxyvitamin D (1,25(OH) 2 D 3 ) or activated vitamin D analogs reduced albuminuria and prevented podocyte injury in 5/6 nephrectomized rats, 9-11 puromycin aminonucleoside-induced podocyte apoptosis, 12 and adriamycin-induced nephropathy. 13 We reported that vitamin D analog therapy reduced albuminuria and prevented podocyte loss in experimental models of type 1 and type 2 diabetes. [14] [15] [16] We also showed that podocytes express the vitamin D receptor (VDR) that is highly inducible by 1,25(OH) 2 D 3 , 17 1, 25 (OH) 2 D 3 transcriptionally stimulated the expression of nephrin, a key slit diaphragm protein synthesized by podocytes, 18 and deletion of VDR in mice led to early onset and robust albuminuria in diabetic state. 19 Together these data suggest that podocytes may be a key antiproteinuric target of vitamin D 20 ; however, no study has directly addressed the renoprotective role of podocyte VDR signaling. In this study, we used transgenic approaches to address this important question. Our data provide strong evidence that podocyte VDR signaling protects podocytes from hyperglycemia-induced apoptosis and prevents diabetic nephropathy.
RESULTS
We used the 2.5 kb human podocin gene (NEPH2) promoter to target human VDR (hVDR) to podocytes in transgenic (Tg) mice ( Figure 1A ). This podocin gene promoter has been well documented for its podocyte specificity in driving transgene expression. 21 To distinguish the hVDR transgene from the endogenous mouse VDR, we tagged the hVDR with a Flag sequence at the N-terminus ( Figure 1A ) so that the hVDR transgene could be detected using anti-Flag antibody ( Figure 1B ). Luciferase reporter assays in VDRE-Luc plasmidtransfected HEK293 cells validated the transactivating activity of Flag-hVDR in response to 1,25(OH) 2 D 3 stimulation (Figure 1C) . The purified 4.1 kb PmeI DNA construct ( Figure 1A ) was microinjected into fertilized embryos isolated from pregnant female DBA/2J mice, a genetic background known to be susceptible to diabetic renal injury. 14, 16, 22 PCR-based genotyping identified 3 positive pups of 62 born from the microinjection, and cross of these founder lines with DBA/2J mice resulted in germline transmission in lines 5 and 12. This study focused on line 5. Similar phenotypes were observed in line 12.
Western blot analysis with anti-Flag antibodies confirmed the expression of Flag-hVDR in the kidney of Tg offspring ( Figure 1D ), which explained the increased VDR levels detected with anti-VDR antibodies in glomerular lysates from Tg mice relative to wild-type (WT) counterparts ( Figure 1D ). Immunostaining of kidney sections with anti-Flag antibodies revealed Flag-positive podocytes in Tg glomerulus but not in WT mice ( Figure 1E ), and the Flag-positive cells in the glomerulus are also Wilms tumor 1 (WT1)-positive (Supplemental Figure 1 ). The hVDR transgene was not detectable in other tissues examined. Together these data demonstrate the establishment of podocyte-specific hVDR Tg mouse lines.
We subjected WT and Tg mice to streptozotocin (STZ) treatment to induce diabetes as reported previously. 14, 16 The mice developed hyperglycemia (blood glucose .400 mg/dl) at 3 weeks after STZ injection. At this point the mice were treated with vehicle (V) (60:40 propylene glycol/H 2 O) or a low dose of vitamin D analog doxercalciferol (Dox) (30 ng/kg, injected intraperitoneally three times per week) for 16 weeks before sacrifice. This dose was one-tenth of the dose that we used previously to prevent albuminuria in diabetic WT mice. 16 Vehicle-treated WTmice developed robust progressive albuminuria during the 16 weeks, and the low dose Dox treatment had little effects on the development of albuminuria in WTmice. In contrast, baseline vehicle-treated Tg mice exhibited significantly reduced albuminuria compared with WT+V mice, and the low dose Dox almost completely blocked albuminuria in Tg mice (Figure 2A ) without altering the blood glucose levels and body weight (Table 1) . Western blot showed that the reduced glomerular VDR levels in diabetic WT mice could not be reversed by the low-dose Dox treatment ( Figure 2B ).
Immunostaining of kidney sections with antibodies against WT1 (nuclear staining) and synaptopodin (cytoplasmic and foot process staining) demonstrated significant podocyte loss in WT+Vand WT+Dox mice and to a less extent in Tg+V mice relative to nondiabetic mice, but podocyte loss was markedly attenuated in Tg+Dox mice ( Figure 2C ), which was confirmed by semiquantitation of WT1-positive cells in the glomeruli ( Figure 2D ). Western blot analyses showed that glomerular fibronectin levels were substantially elevated, and nephrin levels markedly reduced, in WT+V and WT+Dox kidneys compared with the nondiabetic kidneys, but the accumulation of fibronectin was clearly lessened and nephrin levels preserved in Tg+V and Tg+Dox mice ( Figure 2G ). Hyperglycemia-induced decline of slit diaphragm proteins podocin and nephrin was reversed in Tg+Dox mice ( Figure 2H ), the latter consistent with our recent report that nephrin is transcriptionally upregulated by vitamin D. 18 Electron microscopic examination revealed thickening of the glomerular basement membrane (GBM), a marker of glomerular filtration barrier dysfunction, in WT+V and WT+Dox mice, and hVDR overexpression prevented GBM thickening and preserved the morphology of podocyte foot processes (Figure 3, A and B) .
We further explored the renoprotective mechanism of the podocyte VDR signaling. Figure 4G ). These observations suggest that 1,25(OH) 2 D 3 inhibits podocyte apoptosis by targeting p38 activation. The Bcl2 family members play important roles in apoptosis. Western blot analyses showed that glomerular Bcl2 (antiapoptotic) was moderately reduced, and Bad (proapoptotic) levels increased, in WT mice, which were reversed in Tg mice ( Figure 5 , A and B). Because podocyte content only accounts for a small portion of the glomerular lysates, making it difficult to directly analyze glomerular podocytes, we directly examined podocyte cultures to assess the molecular mechanism. Although exposure of podocyte culture to HG had little effects Figure 5 , F-I); however, like p38 inhibitor SB203580 that had no effect on p38 phosphorylation but inhibited its activity to phosphorylate MAPKactivated protein kinase 2 (MAPKAPK2), a downstream substrate p38 kinase, 23 1,25(OH) 2 D 3 , also inhibited HG-induced MAPKAPK2 phosphorylation ( Figure 5 , H and I). Moreover, AngII is known to activate p38 to induce apoptosis, 24 and 1,25(OH) 2 D 3 also blocked AngII-induced MAPKAPK2 phosphorylation ( Figure 5 , H and I). These data are consistent with the podocyte nuclear condensation data reported in Figure 4G , indicating that 1,25(OH) 2 D 3 inhibits p38 activity and p38-mediated signaling in podocyte apoptosis.
The intrarenal renin-angiotensin system (RAS) plays a key role in diabetic renal injury. 25 AngII, the effector of the RAS, is known to promote podocyte apoptosis in vitro and in vivo. 26, 27 Glomerular renin was upregulated in diabetic WT mice, and the hVDR transgene blocked the increase in renin, particularly in the presence of Dox treatment ( Figure 6 , A and B). In podocyte cultures, HG induced the expression of renin and angiotensinogen ( Figure 6 , C and D). As a result, intracellular renin activity ( Figure 6E ) and released extracellular AngII levels in the media ( Figure 6F ) were also markedly increased by HG exposure. These inductions were blocked by 1,25(OH) 2 D 3 ( Figure 6 , C-F). Moreover, HG-induced AT1 receptor expression in podocytes was also attenuated by 1,25(OH) 2 D 3 ( Figure 6G ). These data suggest that the 1,25(OH) 2 D 3 -VDR signaling inhibits the RAS activation in podocytes to suppress HG-induced podocyte apoptosis.
We reported previously that VDR-null (VDRKO) mice developed much more severe albuminuria and renal damage than WT mice in diabetes. 19 To further assess the renoprotective role of podocyte VDR signaling, we asked whether the podocyte-specific hVDR transgene was able to rescue VDRKO mice from developing the severe diabetic renal injury. Transgenic VDRKO (Tg-KO) mice in which only podocytes were reconstituted with hVDR in the VDR-null genetic background were obtained through crossing of Tg and VDRKO mice in DBA/2J background. As expected, VDR expression was detected in the glomerular lysates of Tg-KO mice ( Figure 7A ). In the STZ diabetes model, VDRKO mice developed more severe albuminuria than WT mice as reported previously 19 ; interestingly, albuminuria was markedly attenuated in Tg-KO mice ( Figure 7B ). Diabetes-induced podocyte loss ( Figure 7 , C and D) and glomerular sclerosis ( Figure 7 , E and F) were also more severe in VDRKO mice compared with WT mice, and these phenotypes were ameliorated in Tg-KO mice ( Figure 7 , C-F). Electron microscopy examination of the glomerular filtration barrier revealed severe effacement of podocyte foot processes and thickened GBM in VDRKO mice, and these abnormalities were attenuated in Tg-KO mice ( Figure 7 , G and H). The dramatic increase in glomerular fibronectin levels and decrease in nephrin levels seen in VDRKO mice were mostly reversed in Tg-KO mice ( Figure 7, I and J) . Reconstitution of the hVDR transgene in podocytes was able to attenuate renin induction in the glomerulus, but the effect was not detectable if assayed using whole kidney RNAs ( Figure 7K ). This is expected because hVDR is not expressed outside the glomerulus. Collectively these data demonstrate that by reconstituting VDR signaling only in podocytes could the severe renal injury phenotype seen in VDRKO mice be partly rescued, confirming the critical role of podocyte VDR signaling in renal protection.
DISCUSSION
Although the renoprotective role of vitamin D has been well documented in recent years, the underlying protective mechanism remains elusive. In this study, we provided strong evidence that the VDR signaling in podocytes has potent renoprotective activities against diabetic nephropathy, and the podocyte VDR at least in part mediates the antiproteinuric action of 1,25(OH) 2 D 3 and its analogs. The central mechanistic basis of this protection appears to be the inhibition of podocyte apoptosis induced by hyperglycemia. The data reported here strongly support the speculation that podocytes are key renoprotective targets of vitamin D actions. 20 We assessed the role of the podocyte VDR signaling by a transgenic approach in which hVDR expression was specifically targeted to podocytes using the well characterized podocyte-specific NEPH2 gene promoter. The Flag-tag on hVDR allowed for distinction of the hVDR transgene from the endogenous mouse VDR. We estimated that the NEPH2 promoter-driven hVDR expression increased the podocyte VDR level by about 50% over the WT level. This moderate increase, as we demonstrated, was sufficient to render the Tg kidney resistant to diabetic injury at baseline and more upon vitamin D analog treatment even at a low dose that had no protective effects in WT mice. The hVDR transgene-mediated protective effects were manifested by blockade of albuminuria and attenuation of podocyte damage and glomerular sclerosis. At the molecular level, hyperglycemia-induced decline of slit diaphragm proteins and induction of extracellular matrix proteins were partially reversed, and the activation of the RAS was blocked in Tg mice. Importantly the proapoptotic pathway was partially inhibited. Given the complexity of the diabetic damage process, some of these protective effects of vitamin D might be secondary, but together these data provide novel mechanistic explanations for the renoprotective activity of VDR signaling reported in the literature. 3 Podocyte detachment, due to apoptotic and nonapoptotic reasons, leads to podocyte loss and ultimately to proteinuria. Hyperglycemia may damage podocytes by nonapoptotic mechanisms, but podocyte apoptosis is thought to be one major cause for podocyte loss in diabetic nephropathy. 28 The suppression of podocyte apoptosis seen in Tg mice could be recapitulated in podocyte culture, allowing for more indepth investigations into the underlying molecular mechanism. As reported previously, 29 our data showed that exposure of podocytes to HG-induced program cell death, manifested by increased nuclear condensation and DNA fragmentation. These phenomena were markedly ameliorated in the presence of 1,25(OH) 2 D 3 . In the HG cultural condition, caspase 3 is activated and HG also induced proapoptotic protein Bad and Bak and reduced antiapoptotic protein Bcl2. These effects were attenuated by 1,25(OH) 2 D 3 . For the upstream signaling pathways that have been reported to promote apoptosis, we found that HG induced activation of ERK and p38 MAPK, but not that of Akt. HG-induced activation of p38 and ERK has been documented in podocytes and mesangial cells to cause renal injury. 29,30 1,25(OH) 2 D 3 abrogated ERK phosphorylation and inhibited p38 activity by yet unknown mechanisms. This regulation may be direct or indirect via RAS/ AngII (see below), because AngII is known to active ERK and p38 signaling pathways. We speculate that vitamin D inhibits podocyte apoptosis by blocking these signaling pathways ( Figure  8 ). VDR activation was recently shown to decrease renal inflammation and podocyte apoptosis in diabetic nephropathy models, 31 and the anti-inflammatory activity of vitamin D may also contribute to the inhibition of podocyte apoptosis. Moreover, a recent elegant study demonstrated the involvement of a CD2AP-dendrin-cathepsin L pathway in the regulation of podocyte cytoskeletal structure and survival. 32 This work shows that slit diaphragm injury allows for nuclear translocation of the transcription factor dendrin from the plasma membrane, promoting cathepsin L expression. Cathepsin L acts to alter podocyte actin cytoskeletal organization and renders podocytes hypersensitive to TGF-b proapoptotic signals. The relationship between VDR and this pathway is unknown. Given the role of VDR signaling in the protection of the slit diaphragm, its interaction with this pathway warrants further exploration. It is plausible that vitamin D may regulate podocyte function and survival by targeting this newly identified pathway.
The RAS plays a key role in diabetic renal injury. The proapoptotic activity of AngII toward podocytes has been documented in previous studies. 27 Interestingly, podocytes express all components of the RAS that can be activated by HG, 33, 34 suggesting that the activation of the local RAS in podocytes is able to induce apoptosis of these cells by an autocrine or paracrine fashion. In Tg mice, the induction of renin in the glomeruli by hyperglycemia was attenuated, and the high glomerular renin was reversed by the hVDR transgene in Tg-KO mice ( Figure 7G ). Indeed, HG was able to activate the local RAS in podocytes by induction of renin, angiotensinogen and AT1 receptor, leading to increased production of AngII. In the presence of 1,25 (OH) 2 D 3 , HG-induced activation of the RAS in podocytes was reversed. Therefore, it is clear that vitamin D protects podocytes through blockade of the local RAS activation (Figure 8) . Moreover, the induction of nephrin by 1,25(OH) 2 D 3 , as described previously, 18 also contributes to the protection of podocytes (Figure 8 ). In addition, vitamin D analogs have also been reported to block Wnt/b-catenin signaling in podocytes to ameliorate podocyte damage. 13 Therefore, it is likely that the podocyte VDR signaling regulates multiple pathways to protect the podocytes.
The observation that a low dose of Dox treatment protected the Tg mice but not the WT mice attests to the importance of the podocyte VDR signaling. The VDR mediates the activity of 1,25(OH) 2 D 3 and its activated analogs. Thus when 1,25(OH) 2 D 3 levels are constant, the abundance of VDR in cells largely determines the hormonal activity. VDR expression is highly inducible in podocytes by 1,25(OH) 2 D 3 , but the baseline podocyte VDR expression level is usually low. 18 Therefore, VDR expression in podocytes needs to be upregulated by the vitamin D hormone to be renoprotective. It is possible that the low-dose Dox was insufficient to induce the endogenous VDR in podocytes in WT mice ( Figure 2B ), but in Tg mice the hVDR is constitutively expressed in podocytes, which is sufficient to transduce the activity of Dox and the endogenous vitamin D hormone leading to protection.
The rescue of VDR-null mice by the hVDR transgene further confirms the renoprotective property of the podocyte VDR signaling. In Tg-KO mice, only podocytes express hVDR, whereas the rest of the body is VDR deleted. In this VDR-null background, the systemic level of 1,25(OH) 2 D 3 , which is mainly produced from the proximal tubular cells in the kidney, is extremely high (.10 fold the normal level) because of the lack of feedback suppression. 35, 36 In Tg-KO mice this high level of 1,25 (OH) 2 D 3 was not able to act on cells except the podocytes. Therefore, the rescue of diabetic renal injury observed in the Tg-KO mice is a very compelling piece of evidence that supports the importance of the podocyte VDR signaling in renoprotection. Taken together, these data demonstrate podocytes as a key therapeutic target in vitamin D therapy of CKD.
CONCISE METHODS

Generation of Transgenic Lines
To tag hVDR, the Flag nucleotide sequence GATTACAAGGATGAC-GATGACAAG was PCR-added to the N-terminus of hVDR cDNA coding sequence. The Flag-hVDR sequence (1.3 kb) was then placed under the control of the 2.5 kb human podocin gene (NPHS2) promoter (provided by Dr. Larry Holzman, University of Michigan), 21 followed by SV40 T antigen poly(A) sequence ( Figure 1A ). The 4.1 kb PmeI-PmeI DNA construct was purified for microinjection performed by the Transgenic Mouse Core Facility at the University of Chicago, using fertilized embryo in DBA/2J background. Pups born from the microinjection were screened by PCRbased genotyping using hVDR-specific primers. Transgene-positive mice were crossed with DBA/2J mice to obtain germ line transmission. To obtain VDR-null mice in DBA/2J background, VDR(+/2) mice in C57BL/6 background 35 were backcrossed with DBA/2J mice for 10 generations before being used for interbreeding to generate VDR(2/2) mice for this study.
Diabetic Animal Models and Treatment
Six-week-old male mice were made diabetic by intraperitoneal injection of 35 mg/kg of STZ per day freshly prepared in 10 mM citrate buffer (pH 4.2) for 5 consecutive days as previously described. 14, 16 Three weeks after STZ treatment the diabetic mice were treated with vehicle (60:40 propylene glycol/H 2 O) or Dox at 30 ng/ kg (injected intraperitoneally three times per week) for 10-16 weeks. Nondiabetic mice without drug treatment served as control. Blood glucose was monitored biweekly using CONTOUR glucometers (Bayer). Spot urine was collected monthly, and urinary albumin and creatinine levels were determined using commercial kits as reported previously. 14, 16 Immediately after sacrifice, kidneys were harvested for histologic and biochemical analyses. All mice were fed the 2018 Teklad rodent diet containing 1.5 IU/g of a vitamin D 3 and 38 mg/g of cholecalciferol and exposed to a 12:12-hour light-dark cycle. The Institutional Animal Care and Use Committee at the University of Chicago approved all animal studies.
Histology and Immunostaining
Freshly dissected kidneys were fixed overnight with 4% formaldehyde in PBS (pH 7.2) and processed as described. 14, 16 Kidney sections were stained with PAS. Semiquantitative scoring of glomerular sclerosis was performed using a five-grade method described previously. 14, 16 For immunostaining, frozen tissues in optimal cutting temperature (OCT) compound were cut into 5-mm sections. The sections were stained with antibodies against synaptopodin conjugated with Alexa 647, or with anti-WT1 antibodies (Santa Cruz Biotechnology), followed by incubation with Cy3-conjugated second antibody. Antigens were visualized with a fluorescence microscope.
TUNEL Staining
TUNEL staining was performed with the ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit (Chemicon) according to the manufacturer's instructions. TUNEL-positive cells were semiquantified by randomly counting 100 glomeruli in each mouse. 
Podocyte Culture
Conditionally immortalized mouse podocytes, kindly provided by Dr. Peter Mundel (Albert Einstein College of Medicine), were cultured as previously described. 37 Briefly, podocytes were grown under permissive conditions at 33°C with RPMI 1640 containing 10% FBS, 50 U/ ml g-IFN, and 100 U/ml penicillin/streptomycin. The g-IFN concentration was gradually reduced to 10 U/ml in successive passages. Cells were allowed to differentiate in g-IFN-free media at 37°C for 14 days with media changes every other day. Differentiated podocytes were serum starved in RPMI containing 0.5% FBS and low D-glucose (5. In some experiments, the cells were treated with 100 nM AngII in LG condition for 24 hours. Cells were harvested with Trizol for RNA assays and with radioimmunoprecipitation assay (RIPA) buffer for protein assays.
AngII Assays
AngII levels in the media of podocyte cultures were determined using a Human/Mouse/Rat Angiotensin II Enzyme Immunoassay Kit (Ray Biotech Inc) according to the manufacturer's instructions.
Renin Activity Assays
Renin activity in podocyte lysates was determined using a Fluorometric Sensolyte 520 Mouse Renin Assay Kit (AnaSpec Inc) following the manufacturer's protocol.
DNA Fragmentation Assays
Podocyte genomic DNA was purified using the DNeasy DNA purification system (Qiagen, Valencia, CA). DNA ladders were assayed by ligasemediated PCR using a commercial kit (Clontech, Palo Alto, CA) according to the manufacturer's instructions. Briefly, genomic DNA was ligated to PCR primer sequences by T4 DNA ligase (18 hours Original magnification, 3400 in C; 3200 in E; 325,000 in G. GS, glomerulosclerotic; ND, nondiabetic.
at 16°C). Twenty nanograms of ligated DNA was used as the template for PCR (23 cycles at 94°C for 1 minute/72°C for 3 minutes). PCR products were resolved on 1.3% agarose gel by electrophoresis and visualized by ethidium bromide staining. PCR amplification of gene En-2 (26 cycles at 94°C for 1 minute/70°C for 1 minute) served as the internal control.
Western Blotting
Kidneys, cells, and isolated glomeruli were lysed in RIPA buffer with a cocktail of proteinase inhibitors (Roche). Protein concentrations were determined using a bicinchoninic acid protein assay reagent kit (Pierce). Proteins were separated by SDS-PAGE and Western blotting was carried out as previously described, 38 using the following antibodies: nephrin (Fitzgerald Industries International Inc); fibronectin and actin (Sigma); active caspase 3, angiotensinogen, VDR, renin, Bad, Bcl2, p53, and Bax (Santa Cruz Biotechnology); and ERK, p-ERK, p38, p-p38, Akt, p-Akt, p-MAPKAPK-2, and MAPKAPK-2 (Cell Signalling Technology). Secondary antibody was horseradish peroxidase-conjugated anti-rabbit IgG (Pierce Biotechnology), and signals were detected using SuperSignal West Dura Extended Duration Substrate (Pierce). The relative amount of proteins was quantified using UNSCAN-IT gel analysis software (version 5.3; Silk Scientific, Orem, UT).
RT-PCR
Total RNAs were isolated using Trizol reagents (Invitrogen, Carlsbad, CA). First-strand cDNAs were synthesized from 2 mg RNAs using Moloney murine leukemia virus RT and hexanucleotide random primers. The first-strand cDNAs served as the template for the PCR performed using a Bio-Rad DNA Engine. Real-time RT-PCR was performed in an Applied Biosystems 7900 Real Time PCR System using SYBR green PCR reagent kits (Applied Biosystems, Foster City, CA) as described previously. 19 b-2 microglobulin served as the internal controls.
Electron Microscopy
Tissue blocks of kidney cortex were fixed in 2% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) and then postfixed in 1% osmium tetroxide. Electron microscopy analyses were performed as described previously. 14 
Statistical Analyses
Data were presented as means 6 SEM. Statistical comparisons were carried out using the unpaired two-tailed t test or one-way ANOVA as appropriate, with P,0.05 considered statistically significant. Figure 8 . Vitamin D targets pathways that are involved in apoptosis of podocytes. Hyperglycemia activates p38 MAPK-and ERK-mediated signaling pathways to induce podocyte apoptosis. 1,25-dihydroxyvitamin D (VD) inhibits the induction of angiotensinogen and renin by HG, leading to suppression of AngII production. VD may also suppress p38 or ERK activation via an AngII-independent mechanism. VD upregulation of nephrin also contributes to the protection of podocytes.
